Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 27641-27650 Newer>

The Motley Fool December 11, 2007 Sham Gad	One Fool's Best Stock Tip for 2008 Read on for an investing idea that may help deliver some fantastic returns for years to come.
The Motley Fool December 11, 2007 Dave Mock	Stale IPO, Enticing Prospects Entropic's IPO gets a lackluster start, but be patient, it could build to a nice finish.
The Motley Fool December 11, 2007 Dave Mock	AT&T Shows Investors the Money Thanks to strong operations across its business segments, the company announces a dividend increase of 12.7%, as well as a 400-million-share repurchase plan.
The Motley Fool December 11, 2007 Brian Lawler	Oncology Duo Takes a Gamble With trials complete, Medarex and Bristol-Myers-Squibb plan to submit less-than-stellar data on their skin cancer drug to the FDA.
The Motley Fool December 11, 2007 Tim Beyers	Welcome to the Party, NetSuite After months of preparation, would-be on-demand software star NetSuite is finally in the process of going public.
The Motley Fool December 11, 2007 Toby Shute	Quick Take: Thank You for Not Growing Pacific Ethanol announces it has suspended construction on one of its new ethanol projects until market conditions improve; the market cheers.
The Motley Fool December 11, 2007 Brian Lawler	The MGI Deal Makes Sense MGI Pharma announces it is being acquired by Japanese pharma giant Eisai for $3.9 billion.
The Motley Fool December 11, 2007 Toby Shute	LDK's Big Day German giant Q-Cells orders up six gigawatts of wafers from beleaguered LDK, to be delivered over a 10-year period.
The Motley Fool December 11, 2007 Alyce Lomax	Wal-Mart Digs Deeper Into China The retail behemoth recently won approval from the Chinese government to open its 100th store in that country. It plans to continue expanding in China at a rate of more than 30% per year.
The Motley Fool December 11, 2007 Brian Orelli	Mucous Migrates East U.K.-based Reckitt Benckiser purchases Adams Respiratory Therapeutics, makers of Mucinex, for $2.3 billion.
<Older 27641-27650 Newer> Return to current articles.